Synthetic, self-replicating RNA vectors comprising sequence encoding at least one immortalization protein, and use of the self-replicating RNA vectors to extend the lifespan of primary cell populations and expand said populations of primary cells.

Provided herein are bovine cells that are adapted to grow in growth medium that contains low-serum or no serum and methods thereof. Also provided are food products made from bovine cells cultivated in vitro and methods for harvesting the cells.

An in vitro culture system of human embryonic stem (hES) derived cells is used as a synthetic lethality screening platform for cells undergoing alternative lengthening of telomeres (ALT).

Disclosed herein are methods and compositions for generating immunotherapeutic cells (e.g., NK and T cells) with enhanced cytotoxicity and capacity for expansion thereof. The methods and compositions disclosed herein can further be used for enhanced expansion of CAR-modified NK and T cells with increased cytotoxicity.

The specification describes an improved serum-free animal cell culture medium, which can used for the production of a protein of interest. Ornithine, or a combination of ornithine and putrescine can be added to serum-free media or chemically defined media to improve viable cell density, to reduce cell doubling time, and to increase the production of a protein of interest.

Disclosed are methods for conditionally immortalizing stem cells, including adult and embryonic stem cells, the cells produced by such methods, therapeutic and laboratory or research methods of using such cells, and methods to identify compounds related to cell differentiation and development or to treat diseases, using such cells. A mouse model of acute myeloid leukemia (AML) and cells and methods related to such mouse model are also described.

The present invention relates to cells with altered cell cycle control. In particular, the present invention provides cells with altered cell cycle control and uses of such cells to identify metabolically active agents.

The present invention describes transgenic animals with human(ized) immunoglobulin loci and transgenes encoding human(ized) Igα and/or Igβ sequences. Of particular interest are animals with transgenic heavy and light chain immunoglobulin loci capable of producing a diversified human(ized) antibody repertoire that have their endogenous production of Ig and/or endogenous Igα and/or Igβ sequences suppressed. Simultaneous expression of human(ized) immunoglobulin and human(ized) Igα and/or Igβ results in normal B-cell development, affinity maturation and efficient expression of human(ized) antibodies.

Antiviral compounds, compositions and method are presented. The composition comprises a first antiviral compound and a second antiviral compound, as described herein, optionally a third antiviral compound, as described herein, and an excipient. The excipient may be pharmaceutically acceptable. The excipient may comprise at least one compound that does not occur naturally with a combination of antiviral compounds as described herein in nature. The method comprises administering a pharmaceutical composition comprising a combination of antiviral compounds as described herein and a pharmaceutically acceptable excipient to a patient who has, is suspected of having, or is susceptible to a viral infection.

Provided is a method for producing platelets, in which damage to platelets is suppressed compared with a method in which platelets are separated using a filter from a megakaryocyte culture, and then the platelets are concentrated using a hollow fiber membrane and are further washed using the hollow fiber membrane, and purified platelets can be produced in a shorter period of time compared with the time that is taken to perform the above-described method so as to reduce damage to platelets. The method for producing purified platelets of the present invention includes a concentrating step of concentrating a megakaryocyte culture, and a centrifuging step of centrifuging platelets from an obtained concentrate.